

Title (en)
SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS

Title (de)
SUBSTITUIERTE PYRIDIN-DERIVATE ALS ENTZÜNDUNGSCHEMMENDE MITTEL

Title (fr)
COMPOSES PYRIDINE SUBSTITUES PRESENTANT UNE ACTION ANTI-INFLAMMATOIRE

Publication
EP 1028945 B9 20090218 (EN)

Application
EP 98956570 A 19981104

Priority
• US 9823510 W 19981104
• US 6495397 P 19971107
• US 18511998 A 19981103

Abstract (en)
[origin: WO9924404A1] Selected substituted pyridine compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein a. o. X is O, S, S(O), S(O)₂ or NR₂; Y is -C(O)-NR₃-R₄ or -NR₄-C(O)-R₃; R₁ is a cycloalkyl, aryl, heterocyclyl or heteroaryl radical which is optionally substituted by 1-4 radicals of alkyl, halo, haloalkyl, cyano, azido, nitro, amidino, R₁₈-Z₁₈ or R₁₈-Z₁₈-alkyl; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R₁ is 1-3; and provided when Y is -NR₄-C(O)-R₃ and X is O or S, R₁ is other than a 2-pyrimidinyl radical; R₂ is a hydrogen or alkyl radical; R₃ is an aryl or heteroaryl radical which is optionally substituted by 1-5 radicals of alkyl, halo, haloalkyl, cyano, azido, nitro, amidino, R₁₉-Z₁₉ or R₁₉-Z₁₉-alkyl; provided that the total number of aryl and heteroaryl radicals in R₃ is 1-3; and provided when Y is -C(O)-NR₃-R₄, R₃ is other than a phenyl or naphthyl having an amino, nitro, cyano, carboxy or alkoxycarbonyl, are effective for prophylaxis and treatment of diseases, such as TNF- α , IL-1 β , IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving inflammation, pain, diabetes, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

IPC 8 full level
C07D 213/73 (2006.01); **A61K 31/44** (2006.01); **A61K 31/4418** (2006.01); **A61K 31/4427** (2006.01); **A61K 31/443** (2006.01); **A61K 31/4433** (2006.01); **A61K 31/4436** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/444** (2006.01); **A61K 31/496** (2006.01); **A61P 1/04** (2006.01); **A61P 3/10** (2006.01); **A61P 3/14** (2006.01); **A61P 9/02** (2006.01); **A61P 9/10** (2006.01); **A61P 11/00** (2006.01); **A61P 11/06** (2006.01); **A61P 17/00** (2006.01); **A61P 17/06** (2006.01); **A61P 19/02** (2006.01); **A61P 19/06** (2006.01); **A61P 19/08** (2006.01); **A61P 19/10** (2006.01); **A61P 21/06** (2006.01); **A61P 25/28** (2006.01); **A61P 27/02** (2006.01); **A61P 27/16** (2006.01); **A61P 29/00** (2006.01); **A61P 31/12** (2006.01); **A61P 31/18** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **A61P 37/06** (2006.01); **A61P 37/08** (2006.01); **C07D 213/75** (2006.01); **C07D 213/82** (2006.01); **C07D 401/12** (2006.01); **C07D 405/12** (2006.01); **C07D 409/12** (2006.01); **C07D 413/12** (2006.01); **C07D 417/12** (2006.01); **C07D 471/04** (2006.01)

CPC (source: EP US)
A61P 1/04 (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 3/14** (2017.12 - EP); **A61P 9/02** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/06** (2017.12 - EP); **A61P 19/08** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 21/06** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 27/16** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **C07D 213/73** (2013.01 - EP US); **C07D 213/75** (2013.01 - EP US); **C07D 213/82** (2013.01 - EP US); **C07D 401/12** (2013.01 - EP US); **C07D 405/12** (2013.01 - EP US); **C07D 409/12** (2013.01 - EP US); **C07D 413/12** (2013.01 - EP US); **C07D 417/12** (2013.01 - EP US); **C07D 471/04** (2013.01 - EP US)

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Designated extension state (EPC)
AL LT LV MK RO SI

DOCDB simple family (publication)
WO 9924404 A1 19990520; AT E366722 T1 20070815; AU 1306599 A 19990531; AU 742442 B2 20020103; CA 2307552 A1 19990520; CA 2307552 C 20040608; DE 69838070 D1 20070823; DE 69838070 T2 20071025; EP 1028945 A1 20000823; EP 1028945 B1 20070711; EP 1028945 B9 20071128; EP 1028945 B9 20090218; ES 2290997 T3 20080216; JP 2001522834 A 20011120; US 2002035094 A1 20020321; US 6022884 A 20000208; US 6184237 B1 20010206; US 6333341 B1 20011225; US 6458813 B1 20021001

DOCDB simple family (application)
US 9823510 W 19981104; AT 98956570 T 19981104; AU 1306599 A 19981104; CA 2307552 A 19981104; DE 69838070 T 19981104; EP 98956570 A 19981104; ES 98956570 T 19981104; JP 2000520418 A 19981104; US 18511998 A 19981103; US 43141099 A 19991101; US 64286000 A 20000821; US 93228101 A 20010817